Advertisement
ISRG vs NTRA
Which Stock Would AI Choose? Intuitive Surgical (ISRG) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- ISRG operates in robotic-assisted surgery with consistent revenue growth but faces recent pressure from moderating U.S. procedure trends, while NTRA focuses on molecular diagnostics and has delivered stronger recent revenue expansion driven by oncology testing adoption.
- In recent market activity, NTRA shares have outperformed with notable gains tied to positive clinical data releases, contrasting with ISRG’s more tempered price action amid valuation concerns and sector rotation.
- ISRG maintains higher profitability margins and a larger market capitalization, offering relative stability, whereas NTRA exhibits higher growth rates but remains unprofitable with elevated research and development spending.
- Business models differ sharply: ISRG benefits from recurring system and instrument revenue in a capital equipment sector, while NTRA relies on high-volume testing services with expanding indications in precision medicine.
- Market sentiment reflects trade-offs between ISRG’s established competitive position in minimally invasive procedures and NTRA’s momentum in minimal residual disease (MRD) testing supported by recent large-scale study results.
- Relative performance over recent weeks highlights NTRA’s sensitivity to clinical catalysts versus ISRG’s resilience tied to long-term procedure volume trends.
Introduction
Intuitive Surgical (ISRG) and Natera (NTRA) represent distinct segments within the healthcare sector, making their comparison relevant for investors seeking exposure to medical technology and precision diagnostics. ISRG specializes in robotic surgical systems, while NTRA develops molecular testing platforms focused on oncology and other areas. Traders and portfolio managers evaluating growth-oriented healthcare names may find this side-by-side analysis useful for assessing differences in business models, recent momentum, and risk profiles. The comparison draws on observable market data and company developments to highlight relative positioning without favoring either security.
ISRG Overview and Recent Performance
Intuitive Surgical develops and markets the da Vinci surgical system for minimally invasive procedures across multiple specialties. The company generates revenue through system sales, instruments, and services, supported by a large installed base. In recent market activity, shares have traded in a range reflecting broader healthcare sector dynamics and specific procedure growth observations. Quarterly results showed revenue increases year-over-year alongside earnings that exceeded consensus estimates, yet investor focus shifted toward U.S. procedure trends and competitive developments. A peer-reviewed study published in recent weeks demonstrated improved patient outcomes associated with da Vinci procedures compared with alternative approaches across multiple conditions, providing potential support for adoption. Analyst ratings remain generally positive with a moderate buy consensus, though individual adjustments have occurred amid valuation considerations relative to historical levels.
NTRA Overview and Recent Performance
Natera provides cell-free DNA testing services, with Signatera positioned as a key offering for minimal residual disease (MRD) monitoring in oncology. Revenue stems primarily from testing volumes in oncology, women’s health, and organ health applications. Recent market activity featured strong share price gains following presentation of large-scale clinical data at a major lung cancer conference, highlighting prognostic value in resected non-small cell lung cancer cases. Second-quarter results reflected substantial year-over-year revenue growth, prompting an upward revision to full-year guidance. The company continues to expand indications and partnerships while reporting ongoing net losses tied to research investments. Market capitalization and trading multiples reflect expectations around testing adoption rates and reimbursement progress in precision medicine.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing automated trading strategies from hundreds of AI trading bots that operate across thousands of tickers. Only those demonstrating suitability for prevailing market conditions through consistent backtested metrics and adaptive parameters receive placement in this focused section. Available bots span diverse trading styles, timeframes, risk parameters, and performance statistics, allowing users to review detailed historical results and ticker-specific applicability. The platform emphasizes transparency in strategy logic and outcomes to support informed evaluation by active traders.
Head-to-Head Comparison
ISRG and NTRA operate in adjacent but non-overlapping healthcare niches, creating clear trade-offs. ISRG’s capital equipment model delivers recurring high-margin revenue from procedures with established regulatory clearances and global reach, whereas NTRA’s service-based approach scales with test volumes and benefits from rapid expansion into new oncology indications. Recent momentum favors NTRA on clinical data catalysts, while ISRG shows steadier long-term volume trends tempered by near-term growth moderation signals. Risk factors include ISRG’s exposure to hospital capital budgets and competition in robotics, contrasted with NTRA’s dependence on payer coverage and ongoing cash burn. Sector exposure places both in healthcare but differentiates equipment durability from diagnostic innovation cycles, influencing sentiment based on macroeconomic and regulatory environments.
Tickeron AI Verdict
Based on observable factors including trend consistency, recent clinical catalysts, and relative positioning within their respective subsectors, Tickeron’s AI models currently assign a higher probabilistic edge to NTRA for short-term momentum alignment, though ISRG demonstrates greater stability in earnings quality and market leadership. Outcomes remain contingent on execution of growth initiatives and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ISRG is a Buy and NTRA is a Buy.
ISRG | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 86 | 11 | |
SMR RATING 1..100 | 51 | 94 | |
PRICE GROWTH RATING 1..100 | 56 | 35 | |
P/E GROWTH RATING 1..100 | 73 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (54) in the Biotechnology industry is in the same range as ISRG (74) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ISRG’s over the last 12 months.
NTRA's Profit vs Risk Rating (11) in the Biotechnology industry is significantly better than the same rating for ISRG (86) in the Medical Specialties industry. This means that NTRA’s stock grew significantly faster than ISRG’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is somewhat better than the same rating for NTRA (94) in the Biotechnology industry. This means that ISRG’s stock grew somewhat faster than NTRA’s over the last 12 months.
NTRA's Price Growth Rating (35) in the Biotechnology industry is in the same range as ISRG (56) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's P/E Growth Rating (73) in the Medical Specialties industry is in the same range as NTRA (100) in the Biotechnology industry. This means that ISRG’s stock grew similarly to NTRA’s over the last 12 months.
| ISRG | NTRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 37% | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 53% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 64% | 2 days ago 82% |
| Advances ODDS (%) | 2 days ago 67% | 2 days ago 79% |
| Declines ODDS (%) | 16 days ago 60% | 23 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 51% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 65% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ISRG’s FA Score shows that 0 FA rating(s) are green while NTRA’s FA Score has 1 green FA rating(s).
- ISRG’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ISRG’s TA Score shows that 5 TA indicator(s) are bullish while NTRA’s TA Score has 4 bullish TA indicator(s).
- ISRG’s TA Score: 5 bullish, 5 bearish.
- NTRA’s TA Score: 4 bullish, 4 bearish.
Price Growth
ISRG (@Pharmaceuticals: Other) experienced а +4.19% price change this week, while NTRA (@Medical Specialties) price change was +13.16% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.30%. For the same industry, the average monthly price growth was -3.68%, and the average quarterly price growth was +19.86%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +3.57%. For the same industry, the average monthly price growth was +6.10%, and the average quarterly price growth was +54.98%.
Reported Earning Dates
ISRG is expected to report earnings on Oct 20, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+2.30% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+3.57% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement